Comparison of patient clincopathological features across the 2 studies revealed the validation set was composed of smaller proportion of patients with age >55 years old, with ALT <40U/L, with albumin <40 g/L, with poor tumor differentiation, with complete tumor capsule, with tumor larger than 5 cm in size, compared to the training set, as reported in Supplementary Table S4. The gene discussed is ALB; the disease is neoplasm.